Zogenix Company Description
Zogenix is intent on alleviating that nasty migraine of yours. The biopharmaceutical company is focused on developing and commercializing central nervous system (CNS) and pain therapeutic medications. Its two primary product candidates, both in late-stage development, include sumatriptan DosePro and ZX002. The former (previously known as Intraject) utilizes the company's needle-free drug delivery technology and administers sumatriptan for the relief of acute migraines and cluster headaches. The latter candidate is a controlled release formulation of hydrocodone, used for the treatment of chronic pain. Biotechnology veteran Cam Garner founded Zogenix in 2006. The company filed to go public in 2008.
View the Comprehensive Company Description for Zogenix
The Company Description provides a historical perspective of Zogenix's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Zogenix's evolution in the marketplace.
